MX354120B - Molecula para el tratamiento de un trastorno inflamatorio. - Google Patents
Molecula para el tratamiento de un trastorno inflamatorio.Info
- Publication number
- MX354120B MX354120B MX2013013071A MX2013013071A MX354120B MX 354120 B MX354120 B MX 354120B MX 2013013071 A MX2013013071 A MX 2013013071A MX 2013013071 A MX2013013071 A MX 2013013071A MX 354120 B MX354120 B MX 354120B
- Authority
- MX
- Mexico
- Prior art keywords
- treating
- inflammatory disorder
- molecule
- forpreventing
- medicament
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/008—Leishmania antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Abstract
La presente invención se refiere a una molécula de ácido nucleico capaz de inducir una respuesta anti-inflamatoria para usarse como un medicamento, en donde la molécula de ácido nucleico está representada por una secuencia de nucleótidos seleccionada del grupo que consiste de: i. secuencias de nucleótidos que codifican un polipéptido que comprende una secuencia de aminoácidos que tiene al menos 89% de identidad de secuencia con la secuencia de aminoácidos de SEQ ID NO: 1, ii. Secuencias de nucleótidos que comprende una secuencia de nucleótidos que tiene al menos 89% de identidad de secuencia con la secuencia de nucleótidos de SEQ ID NO: 2, iii. Secuencias de nucleótidos de la hebra complementaria de la cual híbrida a una molécula de ácido nucleico de la secuencia de (i) o (ii) y iv. Secuencias de nucleótidos de las secuencias de las cuales difieren de la secuencias de una molécula de ácido nucleico de (iii) debido a la degeneración del código genético.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161484167P | 2011-05-09 | 2011-05-09 | |
| EP11165248 | 2011-05-09 | ||
| PCT/EP2012/058453 WO2012152792A1 (en) | 2011-05-09 | 2012-05-08 | Molecule for treating an inflammatory disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013013071A MX2013013071A (es) | 2014-04-25 |
| MX354120B true MX354120B (es) | 2018-02-14 |
Family
ID=44533499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013013071A MX354120B (es) | 2011-05-09 | 2012-05-08 | Molecula para el tratamiento de un trastorno inflamatorio. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10000538B2 (es) |
| EP (1) | EP2707022B1 (es) |
| JP (1) | JP6176795B2 (es) |
| CN (1) | CN103796675B (es) |
| AU (1) | AU2012252420B2 (es) |
| BR (1) | BR112013028891A2 (es) |
| CA (1) | CA2835258C (es) |
| EA (1) | EA025202B1 (es) |
| ES (1) | ES2670520T3 (es) |
| IL (1) | IL229329B (es) |
| MX (1) | MX354120B (es) |
| PT (1) | PT2707022T (es) |
| SG (1) | SG194850A1 (es) |
| WO (1) | WO2012152792A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6054135A (en) * | 1996-11-14 | 2000-04-25 | Corixa | Compounds and methods for the detection and prevention of T. cruzi infection |
| FR2829767B1 (fr) | 2001-09-14 | 2004-02-27 | Gerard Papierok | Composes peptidiques destines a la prevention et au traitement d'affections chez les mammiferes |
| SA110310855B1 (ar) * | 2009-11-13 | 2014-09-16 | Laboratories Leti S L Unipersonal | استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي |
-
2012
- 2012-05-08 BR BR112013028891A patent/BR112013028891A2/pt not_active Application Discontinuation
- 2012-05-08 WO PCT/EP2012/058453 patent/WO2012152792A1/en active Application Filing
- 2012-05-08 MX MX2013013071A patent/MX354120B/es active IP Right Grant
- 2012-05-08 EA EA201391649A patent/EA025202B1/ru not_active IP Right Cessation
- 2012-05-08 AU AU2012252420A patent/AU2012252420B2/en active Active
- 2012-05-08 CN CN201280033722.6A patent/CN103796675B/zh active Active
- 2012-05-08 US US14/116,301 patent/US10000538B2/en active Active
- 2012-05-08 ES ES12720157.2T patent/ES2670520T3/es active Active
- 2012-05-08 PT PT127201572T patent/PT2707022T/pt unknown
- 2012-05-08 EP EP12720157.2A patent/EP2707022B1/en active Active
- 2012-05-08 CA CA2835258A patent/CA2835258C/en active Active
- 2012-05-08 SG SG2013082771A patent/SG194850A1/en unknown
- 2012-05-08 JP JP2014509710A patent/JP6176795B2/ja active Active
-
2013
- 2013-11-07 IL IL229329A patent/IL229329B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| PT2707022T (pt) | 2018-06-08 |
| BR112013028891A2 (pt) | 2018-04-24 |
| EP2707022B1 (en) | 2018-03-07 |
| NZ617454A (en) | 2015-09-25 |
| AU2012252420B2 (en) | 2016-09-08 |
| US10000538B2 (en) | 2018-06-19 |
| EP2707022A1 (en) | 2014-03-19 |
| US20140206598A1 (en) | 2014-07-24 |
| CA2835258A1 (en) | 2012-11-15 |
| ES2670520T3 (es) | 2018-05-30 |
| JP2014515924A (ja) | 2014-07-07 |
| CN103796675A (zh) | 2014-05-14 |
| IL229329B (en) | 2018-06-28 |
| EA201391649A1 (ru) | 2014-04-30 |
| EA025202B1 (ru) | 2016-11-30 |
| AU2012252420A1 (en) | 2013-11-21 |
| CA2835258C (en) | 2021-04-20 |
| WO2012152792A1 (en) | 2012-11-15 |
| JP6176795B2 (ja) | 2017-08-09 |
| CN103796675B (zh) | 2019-05-14 |
| MX2013013071A (es) | 2014-04-25 |
| IL229329A0 (en) | 2014-01-30 |
| SG194850A1 (en) | 2013-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY34559A (es) | Inhibidores de bromodominios | |
| EP2762476A4 (en) | 1,2,4-triazine-6-carboxamide derivative | |
| GB201216143D0 (en) | . | |
| EP2763672A4 (en) | AZETIDINE INHIBITORS SUBSTITUTED AS 1,3 PDE10 | |
| GB201203412D0 (en) | . | |
| HK1192757A1 (zh) | 取代的 -芳基- -苯基- -三嗪- -胺 | |
| IN2014DN00180A (es) | ||
| IN2014CN04050A (es) | ||
| IN2014DN09798A (es) | ||
| EP2725901A4 (en) | COMPOSITIONS, METHODS AND NECESSARY FOR TREATING LEUKEMIA | |
| IN2014CN00312A (es) | ||
| PL2748147T3 (pl) | Podstawione 2-alkilo-1-okso-n-fenylo-3-heteroarylo-1,2,3,4- tetrahydroizochinolino-4-karboksamidy do terapii przeciwmalarycznych | |
| GB201203063D0 (en) | . | |
| MX2015006616A (es) | Doble direccion. | |
| MX354120B (es) | Molecula para el tratamiento de un trastorno inflamatorio. | |
| GB201117072D0 (en) | Use of non e.164 msisdns | |
| UA68756U (uk) | Фторовмісні ізомерні бісдіоли, що містять азогрупи, як мономери для поліуретанів | |
| UY33560A (es) | Compuestos heterociclicos | |
| UA71312U (uk) | N-β-ГІДРОКСІЕТИЛБЕНЗИЛАМОНІЮ 3,7-ДИМЕТИЛІМІДАЗО [1,2-f]КСАНТИНІЛ-8-ПРОПАНОАТ, ЯКИЙ ВИЯВЛЯЄ АНАЛЬГЕТИЧНУ ДІЮ | |
| GB201115337D0 (en) | Seasontickethub.com | |
| GB201110324D0 (en) | Estreettalk.com | |
| GB201105651D0 (en) | S.f.i. | |
| IN2015KN00386A (es) | ||
| UA80382U (en) | 1-(para-methoxyphenyl)-2-(4,5,6,7-tetrahydro-3h-azepin-2-ylamino)-ethanon hydrochloride having positive inotropic effect | |
| TN2011000372A1 (fr) | جهاز مراقبة وتحكم في استهلاك المياه |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |